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Abstract: Despite recent efforts, prostate cancer (PCa) remains one of the most common cancers
in men. Currently, there is no effective treatment for castration-resistant prostate cancer (CRPC).
There is, therefore, an urgent need to identify new therapeutic targets. The Hippo pathway and its
downstream effectors—the transcriptional co-activators, Yes-associated protein (YAP) and its paralog,
transcriptional co-activator with PDZ-binding motif (TAZ)—are foremost regulators of stem cells and
cancer biology. Defective Hippo pathway signaling and YAP/TAZ hyperactivation are common across
various cancers. Here, we draw on insights learned from other types of cancers and review the latest
advances linking the Hippo pathway and YAP/TAZ to PCa onset and progression. We examine the
regulatory interaction between Hippo-YAP/TAZ and the androgen receptor (AR), as main regulators
of PCa development, and how uncontrolled expression of YAP/TAZ drives castration resistance
by inducing cellular stemness. Finally, we survey the potential therapeutic targeting of the Hippo
pathway and YAP/TAZ to overcome PCa.
Keywords: hippo pathway; YAP/TAZ; prostate cancer; castration resistance; signal cross-talk;
feedback loops
1. Introduction
Prostate cancer (PCa) is worldwide one of the most prevalent cancers in men, with over one million
new cases reported annually [1,2]. Initially, premalignant prostatic intraepithelial neoplasia (PIN) lesions
form, which develop into advanced localized PCa followed by metastasis [3,4]. The prostate gland
consists of luminal, basal, and neuroendocrine cells embedded in fibromuscular stroma (Figure 1) [4,5].
The most commonly reported PCa is acinar adenocarcinoma, which is androgen receptor (AR)-positive
and arises from the prostate gland secretory luminal cell lineage [4,5]. A smaller subset of PCa
develops from the neuroendocrine cell lineage [4,5]. Neuroendocrine tumors are classified as small-cell
carcinoma and are more prevalent following recurrence [4,5] (Figure 1).
Early stages of prostate cancer are managed by surveillance, as well as classical approaches such
as radiation therapy and surgery [6,7]. However, the first line of treatment of locally advanced or
metastatic prostate cancer is androgen deprivation therapy (ADT) [8–10]. Although ADT is effective
initially, patients develop castration-resistant prostate cancer (CRPC) within 1–3 years. CRPC is defined
as PCa that progressed despite castrate serum testosterone levels (<50 ng/dL) [11,12].
Clinical management of CRPC is challenging, which is partly due to the molecular variation
between patients [13]. Several mechanisms activate AR in CRPC patients [12,14]. These include AR
mutations and amplification, which leads to AR hypersensitivity or promiscuity, causing the activation
of AR in response to low androgen levels and non-androgenic steroids [15,16]. PCa expressing some
AR splice variants also overcomes ADT. These alternative AR variants are constitutively active due to
the loss of the C-terminal part of the AR ligand-binding domain [14,17]. Additionally, CRPC patients
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have relatively higher androgen levels compared to healthy males [18], which is due to intratumoral
steroidogenesis, as well as altered adrenal steroid production [18,19]. Notably, ligand-independent
activation of AR also plays prominent roles in CRPC [20]. Despite recent efforts to optimize current
ADT strategies, CRPC remains a global burden. Advanced PCa is characterized by poor prognosis and
high mortality rate, causing approximately 350,000 global deaths annually [1,2]. There is, therefore,
an urgent need to unravel the complex mechanism underlying PCa development, progression, and ADT
resistance in order to identify new druggable targets.
Figure 1. Representation of different cell types in the prostate gland.
The Hippo signaling pathway is a major player in stem cells and cancer biology [21,22].
The Hippo signaling cascade, identified through studies of tumor suppressors in the fruitfly,
Drosophila melanogaster [23], is conserved across species, including humans [24]. It acts as a
crucial regulator of cell growth and proliferation, organ development, cellular homeostasis,
and regeneration [22,25]. The Hippo pathway is regulated by multiple signals such as,
cell-density/polarity, mechanotransduction, nutrients, and via G-protein-coupled receptors [26–29].
Importantly, apparent kinase cascade independent regulation of Yes-associated protein (YAP)/
transcriptional coactivator with PDZ-binding motif (TAZ) also takes place [30–32] (Box 1).
The upregulation of the Hippo pathway downstream effectors, YAP/TAZ, is central in a variety
of solid tumors [21,25,29,33,34]. Prominently, the implications of elevated activity of YAP/TAZ in
prostate cancer (PCa) are becoming apparent.
In this review article, we summarize the expanding evidence linking YAP and TAZ to PCa
development, hormone inhibition resistance, and metastasis. Additionally, we highlight the role of
the Hippo pathway in regulating prostate cancer stem cells and the importance of Hippo–YAP/TAZ
as a potential therapeutic target for PCa, and we stress hitherto outstanding questions of how the
dysregulated Hippo pathway drives PCa onset and development.
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Box 1. Yes-associated protein (YAP)/PDZ-binding motif (TAZ) Regulation by the Canonical
Hippo Pathway.
The Hippo pathway consists of an upstream serine-threonine kinase cascade. The chief kinases are MST1/2
(the mammalian Hippo homolog) and the MAP4K family of kinases, which phosphorylate and, in turn, activates
large tumor suppressor (LATS1/2) [35–45]. When the Hippo kinases are “active”, LATS1/2 phosphorylate and
thereby inhibit the transcriptional co-activator YAP [46] and its paralog TAZ [47], causing their cytoplasmic
retention by protein 14-3-3, AMOT, or degradation [30,48–51]. In contrast, when the kinase module is
“inactive”, dephosphorylation of YAP/TAZ occurs, which allows YAP/TAZ to translocate to the nucleus and
regulate transcription. YAP/TAZ-mediated transcriptional regulation is predominantly via direct binding to
the transcription factors TEAD1–TEAD4 [52–54]. As a consequence, the expression of multiple proliferative
and antiapoptotic genes occurs, such as connective tissue growth factor (CTGF) and cysteine-rich angiogenic
factor (CYR61) [52–54]. Additional kinases were also shown to directly phosphorylate and thereby regulate
YAP/TAZ, such as SRC [55–58], Nuclear Dbf2-related 1/2 (NDR1/2) [59], c-Jun N-terminal kinase (JNK) [60,61],
5’ adenosine monophosphate-activated protein kinase (AMPK) [62–64], and Nemo-like kinase (NLK) [65,66].
Finally, kinase-independent regulation of YAP/TAZ is also taking place [30–32].
2. Hippo/YAP Key Players in Early Stages of Prostate Cancer
Elevated YAP activity is observed in most solid tumors [34], and hyperactive YAP induces the
formation of several carcinomas including liver, lung, breast, sarcoma, and pancreas [21,22,33,67]. YAP
is also identified as a clinical marker for PCa progression [68] and regulator of CRPC [69]. YAP levels
correlate with patients’ Gleason score, prostate-specific antigen (PSA) levels, and extraprostatic
extensions [68,70] (Figure 2).
Additionally, exogenous overexpression of YAP in normal prostate epithelial cells induces
colony formation and increased migration in three-dimensional (3D) cultures [71]. How YAP becomes
hyperactivated and drives PCa initiation and development is currently not clear, but several mechanisms
were recently implicated (Figure 3).
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Figure 2. Schematic overview of YAP activity levels across different stages of prostate cancer (PCa).
YAP regulates multiple stages of PCa [68,70,71].
2.1. E26 Transformation-Specific (ETS) Transcription Factors
ETS-regulated gene (ERG) is a transcription factor that belongs to the E26 transformation-specific
(ETS) family and drives proliferation, apoptosis, and angiogenesis [72]. ERG overexpression in PCa
results due to the fusion on chromosome 21q22 between the first exon of the androgen regulated gene
TMPRSS2 and the coding sequence of ERG [72,73]. This is a relatively frequent translocation, present
in approximately 40–50% of PCa patients [74]. ERG overexpression results in the development of
PCa tumors in aged mice [75]. Mechanistically, ERG induces YAP promoter activity in the hormone
refractory PCa cell model (VCaP cells) [76], and ERG knockdown results in a decrease in YAP protein
levels [75] (Figure 3). ERG both transactivates TEAD4 and directly binds to the CTGF promoter region,
thereby inducing CTGF expression [75]. ETV1, an additional member of the ETS transcription factors,
induces YAP expression in LNCaP cells by recruiting the lysine-specific demethylase (JMJD2A) to
the YAP promoter [77] (Figure 3). ETV1-induced YAP expression in vivo causes PIN lesion formation,
which, when combined with a single copy loss of phosphatase and tensin homolog (PTEN), progresses
to malignant carcinoma [77]. PTEN is a negative regulator of the phosphoinositide 3-kinase/protein
kinase B (PI3K/AKT) pathway, which controls proliferation and apoptosis [78]. PTEN deletions are
identified in around 20% of primary PCa and 50% of advanced PCa [79].
2.2. Polarity Protein (Par3)
Epithelial cells are polarized cells with distinct functional apical and basolateral membrane
domains [80]. Par3, among other polarity proteins, is a major regulator of epithelial cell structure and
function [81,82]. Moreover, loss of Par3 is present in a variety of epithelial tumors [82]. Par3 loss leads
to the formation of high-grade PIN lesions in vivo due to high YAP activity [82]. In this context, Par3
interrupts the NF2-derived recruitment of LATS1 to the plasma membrane [83]. Additionally, PIN
lesions progress to PCa adenocarcinoma when combined with LATS1 loss in the Par3/LATS1 knockout
(KO) murine model [83]. Contradictorily, Par3 sequesters the potent Hippo kinase cascade activator,
kidney- and brain-expressed protein (KIBRA), and prevents it from forming a complex with NF2 [84].
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As a result, KIBRA complexes with Par3 and atypical protein kinase C (aPKC). Knockdown of Par3
expression in PCa cells restores LATS1 and YAP phosphorylation levels, resulting in a lower migration
rate in vitro and lower rate of metastasis in vivo [84]. The findings from both studies suggest that
Par3 expression is lost during tumor initiation, but might be retained in advanced PCa triggering
metastasis [83,84] (Figure 3). The regulation of Par3 in PCa is not fully understood and the interplay
between the Hippo pathway and polarity proteins in PCa requires further investigation.
2.3. Heat Shock Proteins
Heat shock proteins (Hsps) are cellular stress modalities that regulate signaling and
homeostasis [85]. Hsp expression is upregulated in response to chemotherapy and hormonal
therapy [86]. The heat shock protein 27 (Hsp27) is elevated in a variety of tumors such as lung,
breast, and cervical cancers [86]. Hsp27 is utilized by PCa tumor cells to resist apoptosis following
androgen deprivation [87]. Hsp27 acts as a regulator of MST1 via promoting its ubiquitin-mediated
degradation. As a result, LATS1 and MOB kinase activator 1 (MOB1) phosphorylation are reduced,
causing YAP dephosphorylation and nuclear translocation [88] (Figure 3). However, it is worth noting
that ablation of both MST1 and MST2 is needed both in vivo and in vitro to generally impair LATS1/2
activation [89–91], and, in some contexts, inhibition of the MAP4K family of kinases is also necessary
to reduce overall LATS1/2 activity and thereby to increase YAP activity [37,42,45].
Figure 3. Mechanisms of YAP regulation in early stages of prostate cancer. a. Heat shock protein
27 (Hsp27) induces MST1 ubiquitin-mediated degradation, which in turn causes LATS1 and MOB1
dephosphorylation and thereby inactivation, consequently inducing YAP nuclear translocation [88].
b. Two different mechanisms were proposed by which polarity protein (Par3) regulates YAP; (1) Par3
inhibits YAP activity through inducing the recruitment of Neurofibromatosis type 2 (NF2/Merlin) and
LATS1 to the membrane. As a result, LATS1 is activated, which induces YAP phosphorylation and
cytoplasmic retention [83]. (2) Par3 induces YAP activation through the dissociation of kidney- and
brain-expressed protein (KIBRA) from its canonical complex (KIBRA/NF2/ FERM domain-containing
protein 6 (FRDM6)) and drives the recruitment of KIBRA to the Par3/aPKC/KIBRA complex.
Thus, the interaction between KIBRA and LATS1 is disrupted, which induces LATS1 dephosphorylation
and thereby YAP activation [84]. c. E26 transformation-specific (ETS) transcription factors trigger
YAP induction. (1) ETS-regulated gene (ERG) activation drives YAP activation in old aged mice. ERG
induces YAP and TEAD4 promoter activity and thereby triggers YAP target gene expression [75].
(2) ETS translocation variant 1 (ETV1) drives YAP activation by recruiting lysine specific demethylase
(JMJD2A) to the YAP promoter [77].
Cells 2019, 8, 370 6 of 24
3. The Hippo Pathway Promotes Castration Resistance and Metastasis in Prostate Cancer
3.1. Androgen Receptor—Regulator of CRPC Progression
The androgen receptor (AR) is a transcription factor that belongs to the superfamily of steroid
receptor hormones [92]. AR signaling is essential for prostate development and homeostasis [93].
During absence of androgens, inactive AR resides in the cytoplasm bound to heat shock proteins [92].
Upon binding of dihydrotestosterone (DHT), AR dissociates and translocates to the nucleus to
induce gene expression [92]. AR-mediated gene expression occurs via multiple AR coactivators
and AR-mediated recognition of androgen response elements (AREs) on the target gene promoter.
AREs consist of two common inverted hexameric half-sites (5′–AGAACA–3′) separated by three base
pairs [94]. In healthy tissue, tight homeostatic androgen signaling between stromal and epithelial cells
regulate the prostate gland function [93,95]. Disrupted AR signaling is a key event in PCa initiation,
progression, and development of castration resistance [5,96,97]. However, to date, the exact molecular
mechanism via which CRPC develops is yet to be fully explored [93].
3.2. AR and YAP Colocalization
The role of the Hippo pathway in CRPC development and AR regulation recently gained
momentum (Figure 4). Coimmunoprecipitation and immunofluorescence microscopy revealed that
AR and YAP colocalize to and interact in the nucleus [98]. This interaction is androgen-dependent
in LNCaP cells, but androgen-independent in C4-2 cells [98]. C4-2 cells are a hormone-independent
subline of LNCaP cells, representing a clinical CRPC in vitro cell model [99]. Downregulation of
YAP signaling results in the suppression of AR target genes, suggesting that YAP is critical for AR
activity [98].
Interestingly, C4-2 cells harbor low MST1 kinase signaling, and restoring MST1 expression in
these cells results in impeding the YAP–AR nuclear interaction and AR activity [98,100]. One plausible
mechanism for AR upregulation in CRPC patients is, therefore, MST epigenetic silencing [101]. Cellular
myelocytomatosis (c-MYC), a transcription factor that regulates cellular growth and proliferation [102],
is commonly overexpressed in PCa patients, which induces tumor initiation [103]. Mechanistically,
c-MYC is a regulator of the enhancer of zeste homolog 2 (EHZ2), which is a subunit of polycomb
repressive complex 2 (PRC2) [104]. EZH2, a histone methyltransferase, catalyzes the trimethylation
of histone 3 at lysine 27 (H3K27me3) to regulate gene expression [105]. EZH2 functions both as a
transcriptional activator and repressor for specific gene sets in a cell-context-dependent manner [106].
EZH2 acts as a coactivator of the androgen receptor in CRPC [107]. c-MYC induces EZH2 activity via
suppressing microRNA (miR)-26a/b, which results in MST1 promoter silencing [101]. Treating C4-2
cells with JQ1 results in downregulating c-MYC, which in turn induces MST1 expression and decreases
cell survival [101]. However, combining MST1 knockdown with either c-MYC inhibition by 10058-F4
or EZH2 inhibition by GSK126 restores cell survival [101].
LATS2 and AR were, using immunohistochemistry, reported to colocalize within healthy prostate
epithelium patient samples [108]. When in the nucleus, LATS2 and AR form a protein complex,
which binds to prostate-specific antigen (PSA) promoter and enhancer regions [108]. LATS2 suppresses
AR activity through hindering the NH2- and COOH-terminal interaction within the receptor [108].
The activation status of LATS2 was not examined, and whether AR is a direct substrate for LATS2
is unknown; it is, therefore, still an outstanding question if this LATS2-mediated regulation of AR
transcription is phosphorylation-dependent [108]. Importantly, LATS2 levels negatively correlate
with PCa tumor stage, a conserved phenomenon with several other types of carcinomas [108–110].
Paradoxically, LATS2 is in a range of cell types and, in vivo, a YAP/TAZ–TEAD target gene [111–113],
which forms an integral component of a feedback loop that keeps YAP/TAZ–TEAD activity levels in
check [111–113]. Loss of LATS2 expression, but high YAP activity [75,98] and, therefore, impaired
Hippo pathway feedback in high-grade PCa might, therefore, be a defining PCa hallmark. The relatively
low LATS2 levels in PCa might be due to additional YAP/TAZ–TEAD-independent transcriptional
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regulation and/or post-transcriptional regulation of LATS2 protein. It will be critical to establish
if negative feedback loops within the Hippo pathway are prevalent in healthy prostates and, if so,
why these dynamic negative feedbacks might be defective in PCa. Therapeutically reinstating these
negative feedback loops within the Hippo pathway might then be a viable option. Overall, these reports
show that the Hippo kinase cascade and its effector YAP are regulators of AR nuclear localization
and activity.
3.3. The Hippo Pathway, Tumor Microenvironment, and Immune Response Evasion
Cross-talk between the Hippo pathway and the tumor microenvironment is widespread
across multiple solid tumors and regularly operates via a feed-forward loop that drives tumor
progression [21,26,114,115]. YAP/TAZ is a signaling nexus and regulates cell–cell interaction and
cell–stroma interaction through inducing the expression of a range of secretory proteins such as CYR61
and CTGF [31,54,115,116], as well as of components essential for mechanoresponsive plasma membrane
organelles such as caveolae [117], and components and regulatory elements of focal adhesions such as
integrins and cytoskeletal tension [54,118–122]. YAP/TAZ are well-established molecular sensors of
the extracellular matrix (ECM), and both sense the stiffness and composition of the ECM [31,115,118].
In vitro experiments show that cells cultured on high ECM matrix stiffness result in increased YAP/TAZ
nuclear localization and target gene expression [31,115,116,123,124]. In comparison, cells grown on low
ECM stiffness have a higher cytoplasmic fraction of YAP/TAZ [31,115,116,123,124]. This is particularly
important in PCa, as PCa is widely recognized for its rich tumor–stroma interaction [125,126].
Downregulation of α3 integrin causes PCa progression and promotes formation of metastatic
lesions via altering YAP/TAZ activity. Mechanistically, loss of α3β1 in PCa results in the inhibition
of the Abelson-related gene (Arg/abl2) tyrosine kinase cascade, which dephosphorylates the
p190Rho-Guanosine triphosphate (GTP)ase activating protein-(GAP)/p120RAS-GAP (p190RhoGAP/
p120RAS-GAP complex [127]. Consequently, Rho signaling is activated, ultimately causing increased
YAP/TAZ levels, which promotes cellular migration in vitro and metastasis in vivo [127]. However,
it is not entirely clear whether RhoA in this instance acts via the Hippo–LATS kinase cascade or
independently from it. Paradoxically, α3β1 loss inhibited skin tumorigenesis in vivo [128]. Importantly,
ECM regulates multiple cellular cancer properties [129] and it remains unclear whether these effects
are mediated via the Hippo pathway in PCa and importantly whether ECM stiffness is inducing YAP
activity in PCa. Addressing these questions might partly explain the increased YAP expression levels
in PCa patients.
The ability of tumor cells to evade immune response is widely recognized to be a hallmark
of cancer progression [130]. Intriguingly, YAP is partly responsible for this in PCa [131]. In a
PTEN/ SMAD4 knockout PCa mouse model, YAP levels are elevated [131]. In this model, YAP
expression results in myeloid-derived suppressor cell (MDSC) recruitment via the CXCL5/CXCR2 axis.
MDSCs mediate tumor immune response evasion through suppressing T-cell activation, proliferation,
and viability [132]. YAP–TEAD directly binds to the CXCL5 promoter, inducing CXCL5 expression.
Either MDSC depletion, or inhibition of YAP or CXCL5/CXCR2 activity halts tumor progression [131].
Similarly, YAP hyperactivation is observed in the Kras/p53 knockout pancreatic cancer mouse model,
which stimulates chemokines expression and thereby recruitment of MDSCs to tumors [133]. Of note,
YAP governs the recruitment of tumor-infiltrating type II macrophages (M2) in liver carcinoma, which
promotes tumorigenesis by avoiding immune clearance [134] (Figure 4). However, how the Hippo
pathway gets dysregulated and drives PCa tumor–stroma interactions is still not fully understood.
3.4. TAZ’s Role in Metastasis
YAP and TAZ are modulators of cell motility and cytoskeletal dynamics in a feedback dependent
manner [119]. TAZ in particular is a potent regulator of epithelial–mesenchymal transition (EMT) in
most types of solid cancers, including ovarian cancer, glioma, and breast cancer [135–140]. The role of
TAZ in PCa tumor progression and the regulatory nature between TAZ and AR is not well described.
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TAZ overexpression induces malignant transformation of the non-cancerous prostate epithelial cells,
RWPE-1 [141]. Knockdown of TAZ in PCa cells causes reduction in migratory rate in two-dimensional
(2D) cultures, as well as lower metastatic rate when injected in vivo. Endogenous expression of TAZ is
regulated by ETS transcription factors members ETV1/4/5 (Figure 4) [141]. ETV1/4/5 induce TAZ gene
expression, which results in the expression of SH3 domain-binding protein 1 (SH3BP1) via TAZ–TEAD.
SH3BP1 belongs to the RhoGAP protein family and regulates Rac signaling to modulate cytoskeletal
dynamics and cell motility [142]. So far, the PCa stage-specific levels of TAZ in PCa tumor samples are
yet to be investigated.
Figure 4. The Hippo pathway regulation of advanced prostate cancer. a. During androgen deprivation,
Wingless (WNT) signaling drives the nuclear translocation of YAP and AR, resulting in YAP and
AR target gene induction [143]. Additionally, YAP and AR colocalize in the nucleus and induce
gene expression independently from WNT signaling or androgen availability [98]. b. α3β1 integrin
stimulates the kinase activity of Arg/Abl, which phosphorylates 190RhoGAP, resulting in the inhibition
of RhoA GTPases. Consequently, YAP/TAZ are phosphorylated via LATS1 activity and/or actin
rearrangement and retained in the cytoplasm. α3β1 loss results in the disruption of this signaling
cascade, inducing prostate cellular migration and metastasis [127]. c. PTEN and SMAD4 activity loss
results in YAP hyperactivation. YAP signaling induces the recruitment of inflammatory cells [131].
d. LAST2 impedes AR receptor activity and restricts the binding of AR to the prostate-specific antigen
(PSA) promoter [108]. e. EZH2 and c-MYC cooperate to induce methylation and silencing of MST1,
which might induce AR activity [101]. g. ETV1/4/5 activate TAZ, triggering metastasis via the induction
of SH3BP1 [141].
4. The Hippo Pathway’s Role in Prostate Cancer Stem Cells
The development of CRPC following androgen deprivation therapy (ADT) is often inevitable [144].
CRPC likely develops from the prostate cancer stem cells (PCSCs), a subset of cells within the tumor
which regulate initiation, but importantly also recurrence [145]. PCSCs were successfully isolated from
patient tissue samples on the basis of their α2β1hiCD133+CD44+ phenotype [146–149]. PCSCs have a
high proliferation rate and increased ability of colony formation in 3D cultures, as well as an ability
to form prostate-like structures when injected in immunocompromised mice compared to CD44−
and CD133− cells [146–149]. The Hippo pathway regulates cancer stem cells (CSCs) within a variety
of tumors [136,150,151]. Interestingly, PC3 and DU145 cells resistant to the chemotherapeutic agent
docetaxel possess a CD44+ phenotype. In this context, CD44 increases cellular migration rate in 2D
cultures via inducing YAP, CYR61, and CTGF expression [152].
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The stemness regulator microRNA, cluster miR-302–367, downregulates LATS2, which results in
YAP dephosphorylation and nuclear translocation [153]. Additionally, miR-302–367 overexpression in
LNCaP cells induces their capacity to form spheres in 2D cultures and xenograft tumors when injected
into castrated mice [153]. Cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type
5 (PDE5) also induces stemness via the Hippo pathway [154]. Pharmacological PDE5 inhibition or
inhibition via endogenous nitric oxide results in the activation of cGMP-dependent protein G (PKG);
this activates MST1/LATS1 phosphorylation causing TAZ cytoplasmic retention and degradation [154].
AR further inhibits the transcriptional activity of YAP in LNCaP, as well as in the serially propagated
castration-induced regression derived 22rv1 cells. Mechanistically, AR complexes with EZH2 and DNA
methyltransferase 3 (DNMT3a) at the YAP promoter, causing its methylation and silencing [155]. In this
sense, during androgen deprivation therapy, AR inhibition results in YAP transcriptional activation.
YAP expression results in the transcription of stemness-stimulating genes in a TEAD-dependent
manner, which induces sphere formation in vitro [155]. Additionally, inhibiting YAP activity in vivo
prevents PCa recurrence in castrated TRAMP mice [155] (Figure 5).
Figure 5. YAP/TAZ regulate prostate cancer stem cells (PCSCs). a. Inhibition of the stemness
regulator cyclic GMP-specific phosphodiesterase type 5 (PDE5) by nitric oxide causes activation of
cGMP-dependent protein G (PKG), which activates MST1/LATS1 and causes TAZ phosphorylation [154].
b. Stemness regulator microRNA (miR)-302–367 cluster induces LATS2 dephosphorylation which
results in YAP nuclear translocation [153]. c. DNMT3a and EZH2 form a heterotrimeric complex with
AR, which translocates to the YAP promoter inducing its silencing [155].
5. Targeting the Hippo Pathway for Prostate Cancer Therapy
5.1. Targeting YAP/TAZ–TEAD
The Hippo pathway is a critical regulator of several hallmarks of PCa. Targeting Hippo–YAP/TAZ
clinically, therefore, has therapeutic potential. As YAP/TAZ are transcriptional coactivators that
principally function via binding to the TEAD family of transcription factors [52,53,156–158], the most
direct route to target the Hippo pathway is via this interaction [158]. Verteporfin is a small-molecule
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inhibitor of this YAP/TAZ–TEAD interaction [159]. Verteporfin suppresses CRPC tumor growth and
PCSC proliferation, which ultimately also prevents recurrence [75,98,155]. Although Verteporfin is used
for macular degeneration treatment, its future use for cancer therapeutics is hampered by Verteporfin’s
low solubility and low target affinity, which makes it generally toxic [160,161]. Vestigial-like 4 (VGLL4)
is a tumor suppressor that competitively binds to TEAD via its tondu domain (TDU), thereby preventing
YAP from mediating transcription [162,163]. VGLL4-mimicking peptide (super TDU) abrogates YAP
binding to TEAD4, which has anti-tumor effects in gastric cancer patient-derived cells and in vivo
in the gastric cancer mouse model driven by Helicobacter pylori infection [164]. A YAP-like peptide
(17-mer) was designed aiming to impede YAP–TEAD binding. The 17-mer peptide has higher affinity
for TEAD1 compared to YAP [165,166]. Although targeting the YAP–TEAD interaction appears to be
the most straightforward route toward targeting the Hippo pathway, to date, none of the discovered
agents are approved for cancer therapeutics.
5.2. Statins
Statins are a class of US food and drug administration (FDA)-approved drugs for
hypercholesterolemia treatment [167]. Statins inhibit the enzyme, 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA) reductase, which prevents the conversion of HMG-CoA to mevalonic
acid [168]. Subsequently, statins reduce the synthesis of geranylgeranyl pyrophosphate, which is
required for Rho GTPase activity [169,170]. Statins induce YAP phosphorylation through Rho GTPase
activity and actin rearrangement [169,170]. In vitro, statins induce gap 1 (G1) cell-cycle arrest and
apoptosis in the PCa cell line, C4-2B [171]. Importantly, retrospective studies in a large Taiwanese
cohort of statin-treated heart disease patients showed decreased incidence of PCa [172]. Furthermore,
statins were recently identified to reduce PCa aggressiveness and metastasis incidence significantly in
a retrospective study of a large cohort of Saskatchewan men [173]. Similarly, the occurrence of breast,
ovarian, colorectal, and liver cancer is also reported to be lower in statin users [167]. Nonetheless,
it remains unclear whether this statin-based clinical manifestation is mediated via the Hippo pathway.
5.3. Hippo Kinase Activators
The rapidly accelerated fibrosarcoma (RAF) family of serine/threonine kinases acts upstream
of the MST kinases [174]. RAF-1 suppresses apoptosis by sequestering and preventing MST2
phosphorylation [174]. Inhibition of RAF-1, therefore, results in the activation of MST2. ISIS 1532
oligonucleotide was designed to target the 3′ untranslated region of cRaf messenger RNA
(mRNA) [175,176]. In preclinical trials, ISIS 1532 inhibited lung carcinoma in in vivo mouse
models [175,176]. However, three phase II clinical trials in patients with advanced PCa, and ovarian
and colon cancers showed no significant response, and the agent was withdrawn from further
testing [176–179]. Targeting the Hippo pathway kinases proves challenging as it is regulated by a
variety of external cues and interacts with multiple signaling pathways [161]. In essence, activators
of the YAP/TAZ inhibitory kinases are needed, and designing kinase activators is in general more
challenging than inhibitors [180,181].
6. Signaling Cross-Talk between the Hippo Pathway and Multiple Signaling Pathways
6.1. WNT Receptor Signaling
Upon androgen deprivation, WNT signaling stimulation triggers the nuclear translocation of AR
and YAP to the nucleus, which induces AR-mediated gene expression independently from β-catenin
translocation [143] (Figure 4). YAP and TAZ are downstream effectors of WNT/β-catenin [182,183].
Upon WNT stimulation, YAP and TAZ are released from the WNT destruction complex and translocate
to the nucleus to induce transcription [182,183]. Additionally, WNT-mediated activation of YAP/TAZ
can occur independently from β-catenin via the scaffold protein, adenomatous polyposis coli (APC),
which facilitates SAV1 and LATS1 phosphorylation via glycogen synthase kinase 3 β (GSK-3β)
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activity [184]. Importantly, APC activation mutations are reported in 5% of PCa patients [185].
Contradictorily, knockout of APC in vivo in mouse models results in prostate tumor formation [186].
Impressive work using an array of CripsR knockout cell lines, as well as mouse models, showed that
alternative WNT signlling (Wnt5a/b) activates YAP/TAZ via GPCR α12/13; these G-coupled proteins
signal to activate RhoGTPases that inhibit LATS1/2 activity [139,187]. Whether APC or alternative
WNT signaling activates YAP/TAZ in PCa and whether this mechanism is mediated via androgen
receptor signaling remains unexplored.
6.2. Mechanistic Target of Rapamycin (mTOR) Signaling
The mTOR protein is a central cell growth regulator, which is regulated by growth factors, energy
levels, and nutrients. When active, mTOR stimulates biosynthetic pathways including nucleotide,
protein, and lipid synthesis, while inhibiting catabolic processes, such as autophagy [188,189].
Intriguingly, PCa tumor cells with high PI3K/AKT/mTOR activity are proposed as a mechanism
for prostate tumors to surpass hormone inhibition therapy [190–192]. Additionally, speckle-type
POZ (pox virus and zinc finger protein) protein (SPOP) mutations, the most common mutations
in primary PCa (10%) [74], induce PCa tumorigenesis via PI3K/mTOR [193]. Interestingly, YAP
activates mTORC signaling in breast epithelial MCF10A cells. Mechanistically, YAP suppresses
PTEN activity via miR-29 induction [194]. Consequently, in a transgene YAP mouse model, mTOR
was activated, causing skin hyperplasia [194]. One of the strongest regulators of mTOR activity is
amino-acid sensing; when amino-acid availability of specific amino acids is low, mTOR is switched
off [189]. YAP/TAZ–TEAD induce the expression of a range of cellular amino-acid transporters [195,196],
including the high-affinity hetero dimeric leucine transporter, LAT1 (encoded by SLC7A5 and SLC3A3).
Expression of LAT1 results in increased uptake of leucine at nutrient-limiting conditions [195], as is
prevalent in tumors. Consequently, the expression of amino-acid transporters activates mTOR [195–197].
These mechanisms thereby provide a metabolic advantage for tumor cells with hyperactive YAP/TAZ.
Furthermore, integrin α3 controls YAP phosphorylation and nuclear localization via the focal adhesion
kinase/cell division control protein 42/protein phosphatase 1A (FAK/Cdc42/PP1A) axis, which activates
mTOR [198]. Although these studies were not carried out in the context of PCa, they did indicate
that YAP/TAZ–TEAD activity might be triggering the activation of mTOR in PCa. Remarkably, PTEN
is a negative regulator of YAP activity in the PCa PTEN/SMAD4 knockout mouse model [131]. It is,
therefore, a relevant outstanding question as to whether there is a feedback loop between PTEN
suppression and YAP activity in PCa. Additionally, it remains unclear whether resistance to hormone
inhibition therapy occurs via positive selection of cells with high YAP activity, which in turn induce
tumorigenesis synergistically via TEAD binding and PI3K/mTOR activation.
6.3. Activator Protein (AP-1)
The activator protein (AP-1) transcription factor consists of dimeric complexes, which include
the DNA-binding protein families, cellular ju-nana (c-Jun), cellular FBJ osteosarcoma oncogene
(c-Fos), activating transcription factor (ATF), and cellular musculoaponeurotic fibrosarcoma (c-MAF)
proteins [199,200]. AP-1 activation is mediated via a range of paracrine signaling molecules, as well as
by the mitogen-activated extracellular signaling responsive kinase kinases (MEKs) [199,201,202]. AP-1
regulates multiple cellular responses such as inflammation, proliferation, and apoptosis [200,203].
Importantly, genome-wide analysis revealed that YAP/TAZ–TEAD mediate tumorigenesis by
co-occupying the same genomic region occupied by AP-1 [204,205]. YAP/TAZ–TEAD and the
AP-1 interaction occurs with the aid of the p160 family of steroid receptor co-activators (SRC1-3) [206].
Interestingly, SRC-3 is overexpressed in PCa, which promotes cell proliferation via AR activation [207].
Treating LNCaP cells with DHT induces the activity of c-Jun and tumor necrosis factor alpha (TNF-α)
promoter activity, which contains AP-1 binding sites. In this context, the activation of AP-1 due to AR
induction might synergistically be prompting YAP/TAZ target gene transcription [208]. These findings
provide evidence for cross-talk between YAP/TAZ–TEAD and AP-1. Nonetheless, further investigation
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is required to understand the role of this signaling cross-talk in PCa development and its role in
regulating AR.
7. Conclusions and Perspectives
To date, there are no identified somatic mutations of the Hippo pathway components in PCa.
Furthermore, although YAP was identified to be amplified in a subset of PCa [209], it is evident that
YAP/TAZ is a much more widespread contributor to PCa development. YAP and TAZ play key roles in
multiple stages of PCa initiation, development, and progression, as well as regulation of AR signaling.
However, the mechanistic insights into how YAP/TAZ becomes hyperactivated, how YAP/TAZ interacts
with the stroma and their precise role in PCa development are currently far from fully elucidated.
Obtaining further fundamental understanding of the complexity of YAP/TAZ hyperactivation in PCa
onset and development is, therefore, crucial for improving future clinical interventions and care for
PCa patients [210,211].
• How does YAP drive CRPC development? Androgen receptor bypass is a contributing mechanism
via which PCa cells develop castration resistance [212]. Androgen-deprived PCa cells activate
a variety of hormone receptors such as glucocorticoid receptor (GR) and its targets in order to
overcome androgen dependence [212]. Importantly, GR signaling activates YAP in MDA-MB-231
breast cancer cells [213]. Additionally, the perplexing ability of tumors to activate steroidogenesis
pathways causing AR hypersensitivity is not completely understood. Of note, YAP regulates
steroidogenesis in ovarian granulosa cells [214]. Whether YAP is involved in inducing CRPC via
AR bypass and intratumoral steroidogenesis, and whether YAP is essential for CRPC PCa cell
survival are, to a great extent, still unexplored questions.
• The estrogen receptor (ER) plays an important role in PCa [215,216]. ERα regulates proinflammatory
and pro-proliferative targets and is associated with high Gleason score [215,216]. In comparison,
ERβ receptor plays an anti-inflammatory, pro-apoptotic role [215,216]. Estradiol, the estrogen
receptor agonist, activates the Hippo pathway in the breast SK-BR-3 cell line via G-protein-coupled
estrogen receptor (GPER) [217]. Although anatomically distinct, the molecular and clinical
similarities between breast and prostate cancer [217] highlight the importance of examining if a
similar cross-talk mechanism is occurring in PCa.
• Activation of the Hippo kinase cascade module is a clear direction toward utilizing the Hippo
pathway therapeutically [161,181]. However, an ongoing challenge of this route is the complexity
of the Hippo pathway upstream regulators. Intriguingly, in PCa, it is unclear what causes the
Hippo pathway dysregulation. Delineating the upstream regulators of the Hippo pathway
in a PCa-specific context might, therefore, have direct clinical relevance. Importantly, YAP is
upregulated in CRPC; therefore, developing YAP activity inhibitors is an equally important
therapeutic direction. Successfully controlling YAP and/or TAZ activity state therapeutically
would be an immense step toward developing a personalized therapeutic strategy in CRPC.
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Abbreviations
ADT Androgen deprivation therapy
AMOT Angiomotin
AMPK 5′ adenosine monophosphate-activated protein kinase
AP-1 Activator protein 1
APC Adenomatous polyposis coli
aPKC Atypical protein kinase C
AR Androgen receptor
Arg/abl2 Abelson-related gene
ATF Activating transcription factor
CD133 Cluster of differentiation 133
CD44 Cluster of differentiation 44
Cdc42 Cell division control protein 42
c-Fos FBJ osteosarcoma oncogene
cGMP Cyclin guanosine monophosphate
c-Jun Cellular ju-nana
c-MAF Musculoaponeurotic fibrosarcoma
c-MYC Cellular myelocytomatosis
CRPC Castration-resistant prostate cancer
CTGF Connective tissue growth factor
CXCL5 C–X–C motif chemokine 5
CXCR2 C–C chemokine receptor type 2
CYR61 Cysteine-rich angiogenic factor
DHT Dihydrotestosterone
DNMT3a DNA methyltransferase 3
ECM Extracellular matrix
EMT Epithelial–mesenchymal transition
ER Estrogen receptor
ERG ETS-regulated gene
ETS E26 transformation-specific transcription factors
ETV1/4/5 E26 transformation-specific variant 1/4/5
EZH2 Enhancer of zeste homolog 2
FAK Focal Adhesion Kinase
FDA US food and drug administration
FRDM6 FERM domain-containing protein 6
GAP Guanosine triphosphate (GTP)ase activating protein
GTP Guanosine triphosphate
GR Glucocorticoid receptor
HMG-CoA 3-hydroxy-3-methyl-glutaryl–coenzyme A
Hsp27 Heat shock protein 27
JMJD2A Lysine-specific demethylase
JNK c-Jun N-terminal kinase
KIBRA Kidney- and brain-expressed protein
LATS1/2 Large tumor suppressor 1/2
M2 Tumor infiltration type II macrophages
MAP4K MAP kinase kinase kinase kinases
MDSCs Myeloid-derived suppressor cells
miR302-367 microRNA cluster 302-267
MOB1 MOB kinase activator 1
MST1/2 Mammalian Hippo homolog (Ste20-like kinases)
mTOR Mammalian target of rapamycin
NF2/Merlin Neurofibromatosis 2
NLK Nemo-like kinase
Par3 Polarity protein 3
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PCa Prostate cancer
PCSCs Prostate cancer stem cells
PDE5 Cyclic GMP-specific phosphodiesterase type 5
PI3K-AKT Phosphoinositide 3-kinase/protein kinase B
PKG cGMP-dependent protein G
POZ Pox virus and zinc finger protein
PPA1 Protein phosphate 1
PRC2 Polycomb repressive complex 2
PSA Prostate-specific antigen
PTEN Phosphatase and tensin homolog
RAC Ras-related C3 botulinum toxin substrate 1
RAF Rapidly accelerated fibrosarcoma family of serine/threonine kinases
RhoGAP Rho family of GTPases
SAV1 Protein salvador homolog 1
SH3BP1 SH3 domain-binding protein 1
Super TDU VGLL4-mimicking peptide
TAZ Transcriptional co-activator with PDZ-binding motif
TEAD1-4 TEA domain family member 1–4
VGLL4 Vestigial-like 4
WNT Wingless
YAP Yes-associated protein
17-mer YAP-like peptide
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